* ANI Pharmaceuticals Inc reported quarterly adjusted earnings of $1.34 per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $1.27. The mean expectation of five analysts for the quarter was for earnings of $1.09 per share. Wall Street expected results to range from $1.05 to $1.15 per share.
* Revenue rose 12.5% to $148.33 million from a year ago; analysts expected $144.35 million.
* ANI Pharmaceuticals Inc's reported EPS for the quarter was a loss of $1.27.
* The company reported a quarterly loss of $24.57 million.
* ANI Pharmaceuticals Inc shares had fallen by 2.1% this quarter and gained 5.9% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 0.5% in the last three months.
* In the last 30 days, there have been no negative revisions of earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the pharmaceuticals peer group is also "buy"
Wall Street's median 12-month price target for ANI Pharmaceuticals Inc is 83.00 This summary was machine generated from LSEG data November 8 at 04:20 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 1.09 1.34 Beat
Jun. 30 2024 0.95 1.02 Beat
Mar. 31 2024 1.00 1.21 Beat
Dec. 31 2023 0.86 1.00 Beat
Comments